Wedbush Reiterates Neutral on Fate Therapeutics, Maintains $7 Price Target
Portfolio Pulse from Benzinga Newsdesk
Wedbush analyst David Nierengarten reiterated a Neutral rating on Fate Therapeutics (NASDAQ:FATE) and maintained a $7 price target.
May 06, 2024 | 12:23 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Wedbush analyst David Nierengarten reiterated a Neutral rating on Fate Therapeutics and maintained a $7 price target.
The reiteration of a Neutral rating and maintenance of the $7 price target by Wedbush suggests no significant change in the company's outlook or fundamentals. This is likely to have a neutral impact on the stock price in the short term, as it does not alter the investment thesis or expectations significantly.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100